For example, POLE hypermutation and deficient mismatch repair (dMMR) endometrial cancers may be more sensitive to PD-1/PD-L1 inhibitor-based immunotherapy because they are associated with high mutational burden and significant immune infiltration. Here, POLE is linked to endometrial cancer.